Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.43 |
| ▸ | ACVR2A | P27037 | 4/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22193551 | 0.83 | NLRP3 (0.47) | NLRP3ACVR2ATGFBR2DYRK1ANR4A2 | |
| SCHEMBL29618054 | 0.82 | NLRP3 (0.44) | NLRP3ACVR2ATGFBR2DYRK1AAAK1 | |
| SCHEMBL20634530 | 0.82 | NLRP3 (0.44) | NLRP3ACVR2ATGFBR2DYRK1AAAK1 | |
| SCHEMBL23063345 | 0.82 | NLRP3 (0.47) | NLRP3ACVR2ATGFBR2DYRK1AAAK1 | |
| SCHEMBL22013492 | 0.82 | PARP10 (0.43) | TLR9TLR8TLR7DYRK1AAAK1 | |
| SCHEMBL25671666 | 0.82 | NLRP3 (0.42) | NLRP3ACVR2ATGFBR2DYRK1AAAK1 | |
| SCHEMBL22014926 | 0.81 | ACVR2A (0.42) | NLRP3ACVR2ATGFBR2TLR9TLR8 | |
| SCHEMBL25508130 | 0.81 | NLRP3 (0.44) | NLRP3ACVR2ATGFBR2DYRK1APDE3B | |
| SCHEMBL23844380 | 0.80 | NLRP3 (0.47) | NLRP3ACVR2ATGFBR2DYRK1ANR4A2 | |
| SCHEMBL22827695 | 0.80 | NLRP3 (0.51) | NLRP3ACVR2ATGFBR2DYRK1ANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2024-01-18 | — | — | US | disclosed |
| WO-2023230002-A1 | NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230183258-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-06-15 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2022115417-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20210292336-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2021-09-23 | — | — | US | disclosed |
| WO-2020154499-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183258-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885ACVR2A 4267/4885TGFBR2 3673/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ACVR2A 4354/4885TGFBR2 3449/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ACVR2A 4427/4885TGFBR2 4302/4885 |
| US-20210292336-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885ACVR2A 4267/4885TGFBR2 3673/4885 |
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | NLRP3, PYCARD, NOD1 | NLRP3 1/4885ACVR2A 4811/4885TGFBR2 2707/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ACVR2A 4362/4885TGFBR2 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.